Literature DB >> 8604953

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines.

M B Fennerty1, D Castell, A M Fendrick, M Halpern, D Johnson, P J Kahrilas, D Leiberman, J E Richter, R E Sampliner.   

Abstract

A group of experts from gastroenterology, internal medicine, health economics, medical outcomes, and managed care met in San Francisco, Calif, on September 27, 1994, in an effort to develop clinically and economically effective disease management guidelines to assist physicians in their treatment of gastroesophageal reflux disease in a managed care environment. This article represents a consensus opinion based on the evidence and expert interpretation at the time of that meeting.

Entities:  

Mesh:

Year:  1996        PMID: 8604953

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  14 in total

1.  Gastroesophageal reflux disease: clinical features.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

2.  Significant pressure differences between solid-state and water-perfused systems in lower esophageal sphincter measurement.

Authors:  Philipp Gehwolf; Ronald A Hinder; Kenneth R DeVault; Michael Edlinger; Heinz F Wykypiel; Paul J Klingler
Journal:  Surg Endosc       Date:  2015-02-21       Impact factor: 4.584

3.  Role of esophageal function tests in diagnosis of gastroesophageal reflux disease.

Authors:  M G Patti; U Diener; A Tamburini; D Molena; L W Way
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

4.  Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.

Authors:  S D Mathias; H H Colwell; D P Miller; D J Pasta; J M Henning; J J Ofman
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

5.  Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population.

Authors:  J Kotzan; W Wade; H H Yu
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.

Authors:  N O Stålhammar; J Carlsson; R Peacock; S Müller-Lissner; M A Bigard; G B Porro; J Ponce; J Hosie; M Scott; D G Weir; C Fulton; K Gillon; K D Bardhan
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 7.  Lansoprazole for maintenance of remission of erosive oesophagitis.

Authors:  James W Freston; Robert L Jackson; Bidan Huang; E David Ballard
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia.

Authors:  A Sonnenberg
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 9.  The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.

Authors:  Manishi Prasad; Anne M Rentz; Dennis A Revicki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups.

Authors:  M Iskedjian; T R Einarson
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.